The overall stock score reflects significant challenges in financial performance, particularly in revenue growth and profitability. Technical analysis indicates a neutral trend, with no strong momentum signals. Valuation is reasonable, but the lack of a dividend yield may deter income-focused investors. The absence of earnings call and corporate events data limits additional insights.
Positive Factors
Aftermarket & recurring revenue
A meaningful installed-base aftermarket (lamps, consumables, maintenance and parts) creates recurring, higher-margin cash flows that compound over time. This stabilizes revenue between project cycles, improves lifetime customer value, and supports predictable cash generation and service-led gross margins.
Specialized UV/ozone tech across diversified end-markets
Technical specialization in UV/ozone with exposure to aquaculture, municipal, industrial and maritime markets provides durable demand drivers. Regulatory and compliance needs in water treatment create structural tailwinds and differentiation vs. generalist competitors, aiding long-run market positioning.
Improving leverage and stable equity ratio
Recent improvement in debt metrics and a stable equity ratio indicate better financial flexibility. Reduced leverage risk makes it easier to fund working capital, aftermarket investments and selective capex without excessive refinancing pressure, supporting multi-quarter operational resilience.
Negative Factors
Declining revenue trend
Sustained top-line decline undermines scale economics and the growth of higher-margin aftermarket sales. If revenue contraction continues, it pressures utilization of manufacturing and engineering capacity, limits R&D/project pipeline investment, and reduces ability to improve underlying profitability.
Low net margins and weak ROE
Persistent weak net margins and minimal ROE indicate limited profitability leverage from revenues. Over the medium term this constrains retained earnings, reduces reinvestment capacity for growth initiatives, and may force reliance on external financing for strategic projects.
Inconsistent cash flow conversion
Fluctuating FCF and poor OCF-to-net-income conversion weaken internal funding for maintenance, aftermarket service expansion and working capital. Inconsistent cash conversion increases financing risk and limits ability to sustain investments during cyclical or regulatory-driven project demand phases.
Bio-UV Group SA (ALTUV) vs. iShares MSCI France ETF (EWQ)
Market Cap
€17.78M
Dividend YieldN/A
Average Volume (3M)11.56K
Price to Earnings (P/E)20.3
Beta (1Y)0.42
Revenue Growth-7.99%
EPS GrowthN/A
CountryFR
Employees155
SectorIndustrials
Sector Strength72
IndustryWaste Management
Share Statistics
EPS (TTM)0.10
Shares Outstanding14,154,679
10 Day Avg. Volume12,225
30 Day Avg. Volume11,557
Financial Highlights & Ratios
PEG Ratio-9.61
Price to Book (P/B)0.70
Price to Sales (P/S)0.58
P/FCF Ratio4.56
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.1
Revenue Forecast (FY)€41.80M
Bio-UV Group SA Business Overview & Revenue Model
Company DescriptionBio-UV Group SA (ALTUV) specializes in the design and manufacturing of advanced disinfection systems utilizing ultraviolet (UV) technology. Operating primarily in the water treatment and sanitation sectors, the company offers a range of products that cater to various applications, including swimming pools, aquaculture, drinking water, and industrial processes. Bio-UV Group is committed to providing eco-friendly solutions that enhance water quality while minimizing environmental impact.
How the Company Makes MoneyBio-UV Group generates revenue through the sale of its UV disinfection systems and related equipment. The company has multiple key revenue streams, including direct sales of UV systems to end-users in various industries, ongoing maintenance and service contracts, and the provision of replacement parts for its equipment. Additionally, Bio-UV Group may benefit from strategic partnerships with distributors and industry players that expand its market reach and enhance product visibility. The company also engages in research and development to innovate and improve its product offerings, which can lead to new revenue opportunities in emerging markets.
Bio-UV Group SA Financial Statement Overview
Summary
Bio-UV Group SA faces challenges in revenue growth and profitability, with declining sales and low net margins. While leverage has improved, the company struggles to generate strong returns on equity. Cash flow management shows inconsistencies, highlighting the need for better operational efficiency and strategic financial planning to enhance stability and growth.
Income Statement
45
Neutral
The income statement shows a declining revenue trend with a negative growth rate in the latest year, indicating potential challenges in sales. Gross profit margins have improved over the years, but net profit margins remain very low, suggesting limited profitability. The EBIT and EBITDA margins are modest, reflecting operational efficiency but also highlighting the need for cost control and revenue growth.
Balance Sheet
50
Neutral
The balance sheet reveals a moderate debt-to-equity ratio, which has improved recently, indicating better leverage management. However, the return on equity is minimal, suggesting that the company is not generating significant returns on shareholder investments. The equity ratio is stable, reflecting a balanced asset structure.
Cash Flow
40
Negative
Cash flow analysis indicates fluctuating free cash flow growth, with recent declines. The operating cash flow to net income ratio is low, suggesting challenges in converting income into cash. The free cash flow to net income ratio is relatively healthy, but overall cash flow management needs improvement to support operations and growth.
Breakdown
TTM
Dec 2024
Dec 2023
Dec 2022
Dec 2021
Dec 2020
Income Statement
Total Revenue
38.21M
39.58M
43.13M
51.29M
33.46M
32.17M
Gross Profit
12.61M
24.09M
25.58M
4.71M
1.84M
1.78M
EBITDA
-17.51M
4.18M
4.43M
6.38M
3.35M
1.71M
Net Income
965.41K
31.36K
124.89K
2.42M
689.38K
583.95K
Balance Sheet
Total Assets
73.39M
66.09M
71.41M
74.08M
81.12M
51.92M
Cash, Cash Equivalents and Short-Term Investments
9.36M
3.87M
2.73M
1.98M
10.57M
12.57M
Total Debt
21.11M
23.99M
28.27M
29.15M
30.74M
13.66M
Total Liabilities
32.00M
33.40M
39.19M
41.74M
50.43M
21.72M
Stockholders Equity
41.32M
32.69M
32.22M
32.24M
30.52M
30.20M
Cash Flow
Free Cash Flow
2.27M
5.00M
4.28M
476.03K
571.69K
-3.32M
Operating Cash Flow
4.77M
6.90M
6.24M
2.70M
3.30M
-121.86K
Investing Cash Flow
-1.95M
-1.87M
-1.95M
-8.95M
-20.70M
-3.20M
Financing Cash Flow
3.11M
-3.73M
-3.57M
-2.50M
15.53M
14.35M
Bio-UV Group SA Technical Analysis
Technical Analysis Sentiment
Negative
Last Price1.58
Price Trends
50DMA
1.41
Negative
100DMA
1.49
Negative
200DMA
1.66
Negative
Market Momentum
MACD
-0.03
Negative
RSI
37.68
Neutral
STOCH
44.69
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FR:ALTUV, the sentiment is Negative. The current price of 1.58 is above the 20-day moving average (MA) of 1.31, above the 50-day MA of 1.41, and below the 200-day MA of 1.66, indicating a bearish trend. The MACD of -0.03 indicates Negative momentum. The RSI at 37.68 is Neutral, neither overbought nor oversold. The STOCH value of 44.69 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for FR:ALTUV.
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Nov 01, 2025